[GLP-1-based treatment of type 2 diabetes mellitus].
In: Ugeskrift for laeger, Jg. 169 (2007-05-28), Heft 22, S. 2095-9
academicJournal
Zugriff:
GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.
Titel: |
[GLP-1-based treatment of type 2 diabetes mellitus].
|
---|---|
Autor/in / Beteiligte Person: | Knop, FK ; Vilsbøll, T |
Zeitschrift: | Ugeskrift for laeger, Jg. 169 (2007-05-28), Heft 22, S. 2095-9 |
Veröffentlichung: | Copenhagen : Den Alm Danske Laegerforening, 2007 |
Medientyp: | academicJournal |
ISSN: | 1603-6824 (electronic) |
Schlagwort: |
|
Sonstiges: |
|